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I
n early childhood, 70%–83% of children experience at
least one episode of acute otitis media (AOM) [1,2].
Streptococcus pneumoniae is the most common bacterial
agent identiﬁed as the causative agent of these infections,
although there is increasing evidence that a variety of
respiratory viruses play a prominent role in the development
and pathogenesis of AOM [1]. Even though the heptavalent
pneumococcal conjugate vaccine appears to be making an
impact on the incidence of this disease among children in the
United States, AOM (with more than 24 million diagnoses
annually) remains the leading reason for physician visits and
antibiotic prescriptions among preschool-aged children [2,3].
Frequent use of antibiotics for AOM has led to a vicious cycle
of diminishing returns: increased exposure has led to
increasing drug resistance, which in turn makes the infections
more difﬁcult to treat, necessitating new drugs and more
treatment. Recently, puriﬁed bacteriophage (phage) cell wall
hydrolases, or lysins, have shown promise as novel anti-
infectives due to their ability to eradicate nasal carriage of
gram-positive pathogens, particularly S. pneumoniae [4,5].
These highly active enzymes are produced by phages to
disrupt the bacterial cell wall for the release of progeny
phage. Here, we show that the Cpl-1 lysin, which is speciﬁc for
S. pneumoniae [6], prevents AOM in a novel mouse model that
mimics the natural pathogenesis of this common infection.
Current animal models for AOM have critical limitations.
Modeling AOM in mice requires invasive and artiﬁcial
procedures to establish infection, and sacriﬁce of the animals
to determine outcomes. Larger animals such as chinchillas
and ferrets may develop infection by more natural routes, but
use of these models is limited by their size and complexity
[7,8]. Ideally, we wished to develop a non-invasive mouse
model that was permissive of natural infection. We
engineered a piliated strain of S. pneumoniae, known to
efﬁciently colonize mucosal surfaces (a type 19F strain
obtained from B. Henriques-Normark, ST162
19F) [9], to
express luciferase [10]. Groups of ﬁve mice maintained in a
BL2 facility were infected intranasally with 1310
5 or 1310
6
colony-forming units (CFU) of this bioluminescent strain
under light anesthesia with 2.5% inhaled isoﬂurane using an
established infection model approved by the St. Jude
Children’s Research Hospital animal care and use committee
[11]. Animals were followed daily for development of
infection for two weeks and thrice weekly for another four
weeks. Within 72 hours of pneumococcal infection, 100% of
mice (10/10) were visibly colonized with bacteria in the
anterior portion of their nose, and 70% (7/10) had developed
AOM. These infections of the middle ear all resolved by
bioluminescent imaging within 48 hours, and no mice had
evidence of AOM six days after challenge or later. Nasal
colonization persisted for a median of 27 days (range 17–34
days).
Around half of all children are colonized with S. pneumoniae
[12]. Alteration of eustachian tube function or disruption of
mucosal surfaces through viral infection allows colonizing
bacteria to ascend into the middle ear, triggering AOM [1].
To model this phenomenon, we infected mice that had been
stably colonized by pneumococcus with inﬂuenza virus and
followed them for development of AOM. Although all mice
had been colonized prior to infection with virus, 63% of
virus-infected mice (19/30) developed AOM compared to 0%
(0/10) of mice mock-infected with phosphate buffered saline
(PBS) (Figure 1). Twenty-one of thirty mice in the virus group
had experienced AOM after introduction of the bacteria in
the ﬁrst 72 hours post colonization (with resolution before
viral challenge), while eight of ten mice in the PBS control
group had experienced AOM with resolution (unpublished
data). Both de novo and recurrent infections were seen in the
virus-infected mice, with no correlation to whether they had
previously had AOM. This is the ﬁrst mouse model of AOM in
which infection develops in a manner analogous to that
observed in children.
Using this novel and powerful model, we sought to test our
hypothesis that reduction or elimination of colonizing
pneumococci with puriﬁed Cpl-1 lysin [6] would prevent the
development of AOM. Prior to infection with inﬂuenza virus,
mice colonized with pneumococcus for seven days were
treated twice four hours apart with either 1,000 ug of Cpl-1
intranasally or enzyme buffer (mock treatment). At the time
of the second treatment, nine of ten animals (90%) had
cleared the pneumococcus from the nose, compared to zero
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100% effective in preventing AOM, as no animal treated with
lysin developed a secondary bacterial infection following
inﬂuenza infection, while eight of ten (80%) mice that were
mock-treated developed AOM (Figure 2). In the one mouse in
which colonization persisted despite lysin treatment, the
amount of bacteria present decreased dramatically (78%
reduction in ﬂux of light through the nose). In addition, no
mice treated with Cpl-1 and observed for the duration of
these experiments developed toxicity or illness attributable to
the enzyme as determined by clinical observation, weight loss,
and histopathology (unpublished data).
doi:10.1371/journal.ppat.0030028.g001
Figure 1. Visualization of Bioluminescent Bacteria Inside Live,
Anesthetized Animals Shows the Induction of Otitis Media
(A–B) Six- to eight-week-old female Balb/cJ mice (Jackson Laboratory,
http://www.jax.org) were colonized intranasally with 1310
5 CFU of type
19F S. pneumoniae strain ST162
19F suspended in 100 ll of sterile PBS,
then seven days later either (A) infected intranasally in a volume of 100 ll
of sterile PBS with 100 TCID50 (doses of virus infectious for 50% of tissue
culture wells) of the Mount Sinai strain of influenza virus A/Puerto Rico/8/
34 (H1N1), or (B) mock-infected with sterile PBS. Mice were imaged for 60
seconds daily using an IVIS Lumina Imaging System (Xenogen, http://
www.xenogen.com), and images were analyzed using Living Image
software (version 2.50.1, Xenogen). (A) Pneumococcal load in the nose of
a representative mouse colonized with pneumococcus remained the
same after mock-infection with PBS, while (B) a representative mouse
infected with influenza virus developed otitis media in the left ear.
(C) Although colonization of mice on day 7 did not differ between the
groups (p ¼ 0.56), significantly more mice infected with influenza
developed otitis media than did mock-infected animals (p¼0.00053). An
asterisk indicates a significant difference between the groups using a 2-
tailed Fisher’s Exact test.
doi:10.1371/journal.ppat.0030028.g002
Figure 2. Treatment with Lysin Eliminates Colonization and Prevents the
Development of Otitis Media
(A–B) Mice were colonized intranasally with 1 3 10
5 CFU of S.
pneumoniae and seven days later were infected with influenza virus. Four
hours prior to viral infection, and then again at the time of viral infection,
mice were either (A) treated intranasally with 1,000 lg of Cpl-1 lysin
suspended in 20 ll of enzyme buffer
4, or (B) mock treated with 20 llo f
enzyme buffer. Mice were imaged for 60 seconds daily. (A) A
representative mouse mock-treated with enzyme buffer develops
bilateral otitis media 24 hours after infection with influenza virus, while
(B) a representative mouse treated with lysin clears the colonizing
pneumococci and does not develop a secondary bacterial infection.
(C) Although colonization of mice on day 7 did not differ between the
groups (p ¼ 1.00), significantly fewer mice treated with Cpl-1 remained
colonized 24 hours later (p ¼ 0.00012), and no treated mice developed
otitis media compared to mock-treated animals, in which otitis media
was seen in 80% (p ¼ 0.00036). An asterisk indicates a significant
difference between the groups using a 2-tailed Fisher’s Exact test.
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useful in studies of prevention and treatment of this
important and common infection. Our data on the use of
lysin in the model suggest that a strategy of decolonizing
children of S. pneumoniae may prevent many cases of AOM,
particularly those with chronic AOM. Importantly, these data
also suggest that elimination or even reduction of resident
pathogenic bacteria can prevent secondary bacterial
complications of inﬂuenza. In support of this view, a recent
study of a pediatric pneumococcal vaccine in South Africa
showed a 31% decrease in the incidence of virus-associated
pneumonia compared to controls [13]. Secondary bacterial
infections account for much of the morbidity and
approximately 25% of all deaths during seasonal epidemics of
inﬂuenza, as well as 50%–95% of deaths during pandemics of
inﬂuenza [14]. It is very likely that a reduction in
pneumococcal colonization in susceptible populations such
as infants and the elderly during a pandemic or annual
inﬂuenza outbreak could result in a concomitant reduction in
morbidity and mortality. With worldwide concerns over a
potentially incipient pandemic with highly pathogenic
inﬂuenza viruses of the H5N1 subtype, further study of novel
therapeutics such as phage-derived lysins to prevent these
infections is warranted. &
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